Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder… - European heart …, 2022 - academic.oup.com
Aims We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …
被引用次数：43 相关文章

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.

K Oyama, I Raz, A Cahn, J Kuder, SA Murphy… - European Heart …, 2022 - europepmc.org
Aims We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder… - European heart …, 2022 - snucm.elsevierpure.com
Aims: We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial.

K Oyama, I Raz, A Cahn, J Kuder… - European Heart …, 2022 - search.ebscohost.com
Aims We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder, S Murphy, DL Bhatt… - 2022 - muni.cz
Aims We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder… - European Heart …, 2022 - tohoku.elsevierpure.com
Aims: We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder… - European …, 2022 - utsouthwestern.elsevierpure.com
Aims: We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …
[PDF] archive.org

[PDF][PDF] Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder, SA Murphy, DL Bhatt… - scholar.archive.org
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type
2 diabetes mellitus in the DECLA Page 1 Obesity and effects of dapagliflozin on cardiovascular …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder, SA Murphy, DL Bhatt… - 2022 - pubmed.ncbi.nlm.nih.gov
Aims We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

K Oyama, I Raz, A Cahn, J Kuder… - European Heart …, 2022 - academic.oup.com
Aims We investigated the associations between obesity, cardiorenal events, and benefits of
dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results …